Surface Plasmon Coupled Emission
Accelerating Drug Discovery
Revolutionary Platform Technology
Resonance Biotechnology is poised to redefine the landscape of high-throughput screening (HTS) for drug discovery through its patented Surface Plasmon Coupled Emission (SPCE) technology. SPCE's integration into HTS systems promises to revolutionize this field by enhancing the sensitivity and precision of drug screening processes. By leveraging the unique optical properties of SPCE, researchers can achieve unparalleled detection capabilities, enabling the identification of minute quantities of biomarkers or chemical compounds in vast libraries of potential drugs. This technological advancement is particularly crucial in the early stages of drug discovery, where the ability to swiftly and accurately evaluate the efficacy of numerous compounds can significantly accelerate the development of new therapies.
Unparalled Sensitivity
By utilizing the highly directional emission created by the near-field interaction between fluorophores and surface plasmons on nano-engineered metallic surfaces, our technology offers unparalleled sensitivity. The nano-scale interactions that occur on the metallic surface lead to significant signal-background ratio enhancements, allowing the detection of target molecules with unprecedented specificity and significantly enhancing the efficiency and dependability of screening processes. This advancement pushes the frontiers of pharmaceutical research, opening new possibilities in the development of medical treatments.
Advanced Multiplexing Capabilities
Our SPCE technology harnesses its intrinsic wavelength resolution to deliver unmatched multiplexing capabilities. This innovation dramatically streamlines the complexities typically associated with multiplexing modalities, facilitating the concurrent and accurate analysis of numerous drug compounds. By integrating SPCE technology into high throughput screening workflows, we expect to significantly expedite the drug development timeline, boosting both the dependability and productivity of screening assays. This integration is poised to become a foundational element in the evolution of pharmaceutical research and development, redefining efficiency and precision in the industry entirely.
The Dynamics of Innovation
SPCE technology utilizes a surface-based immunoassay and offers detection of dynamic processes crucial to drug discovery. By integrating time-resolved fluorescence into SPCE, real-time monitoring of dynamic interactions can occur at a level of detail previously unattainable, providing deeper insights into the mechanisms of potential therapeutic targets. As a result, the integration of SPCE into HTS workflows will mark a ground-breaking advancement in the detection of dynamic interactions, effectively accelerating the path from discovery to development in drug research by offering advanced functionality.
